IceCure Medical Ltd (ICCM)

[TechandBio]

FDA Approval coming.

Billionaire who founded Tencent Victor Li owns half the shares.

Freezing Cancer
in its Tracks.

Enabling non-surgical treatment of
Cancerous tumors!
Treats Breast, Kidne, Lung and other cancer indications!

No debt no warrants.

Partnered with Medtronic already in Asia
IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China.

People are realizing minimally invasive platforms are the approach to treating cancer and other diseases.
You can get the treatment done for a few thousand dollars in less than hour with a local anesthetic no anesthesia. and be home within a couple of hours.

Independent 5 year data for breast cancer showing 97% non recurrence rate SAFE am alternative too million dollar plus gene editing treatments and or pills or IV that are expensive and have many major side effects. There are now over half dozen studies done in many countries proving the platform and Data!

PLSE went from $1.00-20.00 2-3 year period they have a billion market cap and no revenue.

ICCM is going has tremendous upside also Japanese approval process starts in January with the largest device company in Japan company Terumo. FDA panel meeting in early November with ICCM and FDA Approval can come late 2024 or January next year!

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.icecure-medical.com/

https://d1io3yog0oux5.cloudfront.net/_bc04737bc474935b6b12dfea965ac04e/icecuremedical/db/2291/21959/pdf/IceCure+Medical+%28ICCM%29+Company+Presentation+-+29-Aug-2024+FINAL.pdf

(Watch this Testimonial Video)

$ICCM

[midastouch017]

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

https://finance.yahoo.com/news/study-published-british-journal-radiology-120000504.html

Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage

Independent study conducted at the European Institute of Oncology (IEO) demonstrates interventional radiology use cases for ProSense® for indications that are approved in various markets across the world

CAESAREA, Israel, Sept. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study led by Dr. Franco Orsi, Director of Interventional Radiology at the European Institute of Oncology (IEO) in Milan, Italy and an expert ProSense® user. The study titled "Liquid Nitrogen-Based Cryoablation: Complication Rates for Lung, Bone, and Soft Tissue Tumors" was published by Oxford University Press on behalf of the British Institute of Radiology.

"Cryoablation with liquid nitrogen has a growing role in early oncology treatments across a wide variety of cancer types and particularly for patients who may have multiple comorbidities and/or who want to avoid surgery. As interventional radiologists are increasingly and effectively using cryoablation, it's important to note Dr. Orsi and his colleagues underscore in the paper that interventional radiology is now the fourth pillar of the oncology field, alongside clinical oncology, surgical oncology and radiation therapy," stated IceCure's Chief Executive Officer, Eyal Shamir. "We are very pleased that ProSense® is providing a minimally invasive option to treat cancer patients early, safely and effectively."

The study assessed the complication rate both during and 24 hours after treatment with IceCure's cryoablation system in 85 patients who were treated for 96 lesions (tumors), 36.4% of which were lesions in bones, 18.8% in lungs, and 44.8% in soft tissue. The primary technical success rate, defined as complete tumor coverage, was 97.7% (83 of 85 patients). Patients with benign and malignant tumors were treated for either curative or palliative intent. Minor complications resolved themselves without intervention or merely required simple interventions such as drainage. The study concluded that cryoablation using an LN2-based system, such as ProSense®, is safe across various tumor sizes and locations, with only minor complications observed.

LN2-based cryoablation was compared to argon-based systems in the study who point to the benefits of LN2 procedures including its suitability for office-based procedures performed under local anesthesia, compared to argon systems which typically require general anesthesia and are therefore less suitable for office procedures. The study also addresses the challenges of argon systems requiring large argon gas cylinders, which necessitate dedicated storage space and trained personnel for transport, as well as the higher cost of the procedure due to the use of multiple cryoprobes as well as the use of noble gases, argon and helium. The study demonstrates that LN2-based systems, such as ProSense®, are more cost effective and easier to manage.

Two previously published independent lung cancer studies of ProSense® in the treatment of lung cancer, which evaluated the procedure's local control and recurrence free rate, reported 96% and 100% three-year recurrence free rates. Independent and IceCure-sponsored studies of other interventional radiology indications are ongoing.

[midastouch017]

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

https://finance.yahoo.com/news/icecure-announces-fda-advisory-panel-120000234.html

Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancer

FDA decision regarding marketing authorization of ProSense® expected by early 2025

CAESAREA, Israel, Sept. 12, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the U.S. Food and Drug Administration's ("FDA") Medical Device Advisory Committee Panel (the "Advisory Panel") is scheduled to take place on Thursday, November 7, 2024. The purpose of the Advisory Panel is for the FDA to obtain independent expert advice on scientific, technical and policy matters related to the De Novo Classification Request for marketing authorization of ProSense® for the indication of treating patients with early-stage low risk invasive breast cancer with cryoablation and adjuvant endocrine therapy.

"This public forum transparency ensures key stakeholders, including women with early-stage low risk breast cancer, their doctors and payors, can exchange views and data regarding the potential benefits of minimally invasive cryoablation with ProSense® as an alternative to surgery," stated IceCure's CEO, Eyal Shamir. "Following the Advisory Panel, we anticipate that the FDA will make a decision regarding marketing clearance of ProSense® by early 2025."

The Advisory Panel will include breast surgeons, interventional radiologists and industry representatives from the regulatory community. The vast body of data available on ProSense® as a treatment for early-stage low risk breast cancer will be reviewed by the Advisory Panel, including results from the Company's ICE3 study, the largest controlled multicenter clinical trial ever performed for liquid nitrogen-based cryoablation of early-stage malignant breast tumors. Per the analysis, at the 5-year follow-up evaluation, 96.3% of the subgroup of patients treated with ProSense® cryoablation, followed by adjuvant endocrine therapy, were estimated to be free from local recurrence. 100% patient and physician satisfaction was reported. The Advisory Panel is expected to make its recommendations at the conclusion of the meeting, at which time the FDA will commence its review process.

The FDA generally makes Advisory Panel meeting materials and the live webcast link available to the public no later than two business days before the meeting, at which time IceCure intends to share the link with shareholders via a press release.

About ProSense®

The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

[it_happens]

$ICCM is in a good loading zone right now.

[midastouch017]

That too.

[it_happens]

$ICCM just needs to make more money.

Forecast is good. https://www.tipranks.com/news/blurbs/icecure-medical-a-strong-buy-on-robust-financials-and-regulatory-advancements?mod=mw_quote_news

[midastouch017]

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

https://finance.yahoo.com/news/uspto-grants-notice-allowance-additional-123000903.html

Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fields

Over 50 patents issued and allowed worldwide for IceCure's platform cryoablation technology

CAESAREA, Israel, Aug. 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for a continuation application based on the Company's issued patent titled "Cryogen Pump". The original patent, which was also issued by the European Patent Office and the Japan Patent Office, as well as the continuation, will be in effect until 2041.

"This new patent will support IceCure's potential for increasing the number of indications, procedures and applications that can be performed with our next-generation industry-leading platform cryoablation systems," stated IceCure Chief Executive Officer Eyal Shamir. "We believe that further fortifying our cryoablation intellectual property ("IP") estate in the U.S. is well timed both with respect to the indications for which we already have U.S. Food and Drug Administration ("FDA") approval as well as the FDA's decision on clearance for early-stage breast cancer, the decision which we expect in the first quarter of next year."

IceCure's novel cryogenic pump is submersible in liquid nitrogen, works in a closed circuit, improves the cooling rate during a procedure, and is designed to be used for multiple procedures or longer duration procedures without the need to refill liquid nitrogen. Moreover, this pump enables the use of a wider range of cryoprobes and catheters. The pump has been integrated into IceCure's next-generation XSense™ cryoablation system.

[midastouch017]

The long and winding road
That leads to ....approval.

[it_happens]

I would like to see the FDA give an approval. Would drive PPS way up.

[midastouch017]

What an FDA approval could do.

[it_happens]

It's not moving much. Very underrated stock.

[midastouch017]

I won't be too surprised if ICCM
eod in the green.

[midastouch017]

Indeed we do. Hopefully it is a Marathon run.

[it_happens]

We have a runner here today

[midastouch017]

If/when FDA aaproval achieved, it is possible.
Until then, hopefuly sales will continue growing,
othewise some sort of partnership from BP will
serve a good enough sp catalyst.

[it_happens]

Looking good today. Maybe get back up to 8s.

[midastouch017]

0.7266 +0.0866 (+13.6722%)
As of 10:39 AM EDT. Market Open.
Volume 920,551
Avg. Volume 423,164

[it_happens]

Getting published in medical journals will help. Company is looking pretty solid.

[midastouch017]

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

https://finance.yahoo.com/news/icecure-medical-reports-20-growth-123000882.html

Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer

Conference call to be held today at 10:00 am Eastern Time

CAESAREA, Israel, Aug. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2024.

Significant Near and Short Term Value Enhancing Catalysts

U.S. Food and Drug Administration ("FDA") Medical Device Advisory Committee expected Q4 2024. The purpose of the meeting is to obtain independent expert advice on scientific, technical, and policy matters related to the Company's De Novo Marketing Clearance Request for a minimally invasive alternative treatment for women diagnosed with early-stage, low risk breast cancer.

The FDA will review and evaluate the recommendation of the Medical Device Advisory Committee and is expected to have a final decision regarding marketing clearance of ProSense® in early-stage, low risk breast cancer by early 2025.

Data from interim results of the Company's ICESECRET, a prospective, multicenter, single-arm clinical trial of ProSense® in the treatment of kidney cancer, is expected to be presented by December 2024.

The Company's partner in Japan, Terumo Corporation, is expected to file for regulatory approval of ProSense® for early-stage low risk breast cancer with endocrine therapy in Japan in the first quarter of 2025, with the aim of receiving clearance and making the Company's cryoablation system more commercially available to physicians and patients alike in Japan.

With 15 ongoing independent studies being performed globally, the Company expects additional third-party data on ProSense® will be published in medical journals and presented at prestigious medical conferences.

"We have achieved all of our primary objectives for the first half of 2024, and we are now in the process of preparing for the FDA Medical Device Advisory Committee, which we expect to be scheduled for Q4," stated IceCure Medical's CEO, Eyal Shamir. "The data from the ICE3 study has been overwhelmingly positive, and with a reported 100% patient and physician satisfaction rate, our goal is to highlight these results and leverage the expert testimony to secure a favorable recommendation from the committee to treat women diagnosed with early-stage, low risk breast cancer, and to ensure we maintain the forward momentum through year-end and into 2025 upon potential clearance from the FDA.

"The U.S. is the largest healthcare market in the world, and as a patient-centric company, we believe it's critically important to offer patients a safe and proven non-surgical procedure with a system that is cleared in 15 countries, including in the U.S. Moreover, we strongly believe that our first half 2024 system and probe sales growth of 20%, notwithstanding the revenue recognition from Terumo, is primarily due to women and their physicians making a conscious choice to use ProSense® and avoid a surgical procedure because it's a win-win scenario for patient, physician, health provider, and payor."

Second Quarter and Recent ProSense® Efficacy & Safety Data Reported by Independent Researchers

ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery: The aim of the study titled "Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients" published in the British Journal of Radiology was to evaluate the acceptance of percutaneous cryoablation treatment by patients with early-stage breast cancer who choose not to have surgery. Of the 45 patients offered cryoablation with ProSense®, 43 patients, or 95.6% accepted. 36 of these, representing 39 malignant tumors (median size 24mm), proceeded to undergo cryoablation. The median age of patients treated with cryoablation was 87, with a range of 60-96. After a median follow-up of 16 months, the complete ablation rate in luminal A and B breast cancer with tumors = 25mm was 100%. No major complications were seen.

Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment in Japan with ProSense®: Data from a study performed in Japan was published in an article titled "Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan," in the journal Breast Cancer. Eighteen early-stage breast cancer patients, with a mean age of 59.0 [±9.0 years], with a mean tumor size of 9.8 ±2.3 millimeters, who underwent treatment with ProSense® were followed for a mean of 44.3 months. No patients had local recurrence or distant metastasis in the 5-year follow-up. No serious adverse events were reported. Cosmetic outcomes were excellent and the overall patient satisfaction level and patient quality of life improved post-cryoablation.

European Study Provided More Evidence Supporting ProSense® Treatment for Metastatic and Recurrent Breast Cancer: Data published in the highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for breast cancer with a low complication rate, high complete ablation rate and satisfactory overall survival (OS), progression free survival (PFS) and local tumor control. The recurrence rate was 8.9% in a population of 45 patients who had previously received various therapies before cryoablation including surgery, radiation therapy, or chemotherapy with tumor sizes of up to 4 centimeters in diameter. Of those patients, 11 had recurrent tumors and 21 had metastatic disease. This higher-risk population contrasts with the early-stage breast cancer patient subjects in IceCure's U.S. ICE3 trial. The European study titled "CT-Guided Percutaneous Cryoablation of Breast Cancer: A Single-Center Experience" was conducted at Goethe University in Germany.

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with ProSense® in Japan: From April 2014 through August 2020, 389 breast cancer patients with tumor lesions of less than 15 millimeters in diameter were treated with ProSense®. The ipsilateral breast tumor recurrence rate (IBTR) was 0.26%, resulting in a 99.74% recurrence free rate. These data were presented at 32nd Annual Meeting of the Japanese Breast Cancer Society, where the demand for minimally invasive breast cancer treatment was an overarching theme.

Financial Results for the Six Months Ended June 30, 2024

Sales of ProSense® systems and disposable probes for the six months ended June 30, 2024 grew by 20% to $1,654,000 compared to $1,373,000 for the six months ended June 30, 2023. The growth was primarily attributable to sales in Europe, the U.S., Japan and other territories in Asia which were partially offset by a decrease in sales in China. Total Revenue for the six months ended June 30, 2024, grew to $1,754,000 from $1,647,000 for the six months ended June 30, 2023 due to an increase in the sale of ProSense® systems and disposables, which was partially offset by a decrease in revenue recognition and other services in Japan of $100,000 and $274,000 in the first six months of 2024 and 2023, respectively.

Gross profit for the six months ended June 30, 2024 grew to $799,000 from $754,000 for the six months ended June 30, 2023. Gross margin for the six months ended June 30, 2024 and for the six months ended June 30, 2023 was 46%. Non-GAAP gross profit for the six months ended June 30, 2024 increased to $699,000 from $480,000 for the six months ended June 30, 2023, an increase of $219,000 or 46%. Non-GAAP gross margin for the six months ended June 30, 2024 grew to 42% from 35% for the six months ended June 30, 2023. The increase in non-GAAP gross profit and non-GAAP gross margin, which exclude revenue from the exclusive distribution agreements and other services in Japan, was attributable to the increase of 20% in revenue from sales of ProSense® systems. Non-GAAP gross profit and non-GAAP gross margin are financial measures that may be defined as "non-GAAP financial measures" by the U.S. Securities and Exchange Commission ("SEC"). For a reconciliation of these non-GAAP financial measures to the nearest comparable GAAP measure, see Appendix A to this press release.

Research and development expenses for the six months ended June 30, 2024 were $3,536,000 compared to $4,190,000 for the six months ended June 30, 2023. The decrease was primarily due to a reduction in development expenses for the XSense™ System, which received FDA clearance in June 2024, and a decrease in clinical and regulatory costs as the Company concluded the ICE3 study in March 2024 and submitted the application to the FDA in April 2024. Sales and marketing expenses for the six months ended June 30, 2024 were $2,296,000 compared to $2,253,000 million for the six months ended June 30, 2023. General and administrative expenses for the six months ended June 30, 2024, narrowed to $1,845,000 from $2,349,000 for the six months ended June 30, 2023.

Total operating expenses for the six months ended June 30, 2024 decreased to $7,677,000 from $8,792,000 for the six months ended June 30, 2023. The decrease in operating expenses was attributable to reductions in research and development, and general and administrative expenses, due to the Company's initiative to reduce non-critical operating expenses which were partially offset by an increase in sales and marketing expenses.

Net loss for the six months ended June 30, 2024 narrowed to $6,690,000 million, or $0.14 per share compared to a net loss of $7,657,000 million, or $0.17 per share, for the same period last year.

As of June 30, 2024, the Company had cash and cash equivalents, including short-term deposits, of approximately $10.5 million, compared to $11 million as of December 31, 2023. As of July 31, 2024, the Company had cash and cash equivalents of approximately $10.3 million. During the first half of 2024, the Company raised $4.7 million in net proceeds from the sale of 3,787,976 ordinary shares under its at-the-market ("ATM") offering facility.

Use of Non-U.S. GAAP Measures

In addition to disclosing financial results prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP), this press release contains certain financial measures which may be defined as "non-GAAP financial measures" by the SEC. The Company defines non-GAAP gross profit as gross profit less revenue from exclusive distribution agreements and other services. The Company has provided non-GAAP gross profit in this press release because it is a key measure used by management and the board of directors as an indication of our gross profit from sales of our systems and disposables and management believes that it is useful to investors' understanding and assessment of the Company's gross profit without the impact of revenue recorded from the Company's exclusive distribution agreements and other services. The Company has provided a reconciliation below of non-GAAP gross profit and non-GAAP gross margin to the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP. The non-GAAP financial measures disclosed by the Company should not be considered in isolation or as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP and the financial results calculated in accordance with U.S. GAAP and reconciliations to those financial results should be carefully evaluated.

Conference call & webcast info:

Tuesday, August 20, 2024, at 10:00 am EDT
US: 1-888-407-2553
Israel/International: [phone]
A live webcast will be available at: https://Veidan.activetrail.biz/IcecureQ2-2024
A recording of the webcast will be available at: ir.icecure-medical.com

About ProSense®

The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors.

[clobal]

Where's your proof

[midastouch017]

Close to no revenue and rs coming soon,
small wonder.

[it_happens]

Surprised more people aren't flocking to this ticker

[midastouch017]

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

https://finance.yahoo.com/news/icecures-prosense-destroyed-100-breast-123000650.html

After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100%

Study concluded that most non-surgical patients with early-stage breast cancer accepted cryoablation when the treatment was offered and that cryoablation is a safe, effective alternative to surgery and well-tolerated as an out-patient procedure

CAESAREA, Israel, Aug. 14, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled "Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients" in the British Journal of Radiology, a publication of the British Institute of Radiology. The single-site study, led by Lucia L. Garna Lopez, PhD, was conducted by researchers in the radiology, oncology, and surgery departments at Hospital Lucus Augusti in Lugo, Spain.


The aim of the study was to evaluate the acceptance of percutaneous cryoablation treatment by patients with early-stage breast cancer who choose not to have surgery. Of the 45 patients offered cryoablation with ProSense®, 43 patients, or 95.6% accepted. 36 of these, representing 39 malignant tumors (median size 24mm), proceeded to undergo cryoablation.

"This study is a good case in point that when women who elect not to have surgery, or are not eligible for surgery, are given the option, they overwhelmingly choose cryoablation to treat their breast cancer," stated IceCure CEO Eyal Shamir. "In addition to providing excellent data on the safety and efficacy of ProSense® in patients who chose not undergo surgery, the study's authors also point to the correlation between a larger aging population, increased risk of breast cancer with age, and the fact that most patients who elect not to have surgery or are not eligible are elderly patients. These factors, we believe, point to increasing demand for ProSense® when it is presented as an option."

The median age of patients treated with cryoablation was 87, with a range of 60-96. After a median follow-up of 16 months, the complete ablation rate in luminal breast cancer with tumors ≤ 25mm was 100%. No major complications were seen.

The study investigators concluded that most non-surgical patients with early-stage breast cancer accepted cryoablation when the treatment was offered and that cryoablation is safe, effective, and well-tolerated as an outpatient procedure. The published article went on to state that outcomes suggest cryoablation could be an alternative to surgery for the management of breast cancer in this group of patients and pointed to financial, physical, and cosmetic benefits.
About ProSense®
The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors.

[it_happens]

Hopefully, they can get a peace deal done soon. I think they are leaning that way right now. Without a peace deal, more countries might get drawn into the conflict.

[Optionsrbest4u]

Would much prefer and expect the company go for say $10M vs. '30 or 40 Million' - but then I haven't spoken with anyone as you have. Even $30M seems like some very serious dilution. BTW...I'm surprised the company spokesman you spoke with, whoever that is, was willing to be so specific.

[TechandBio]

Lots of political things going Hamas Leader Killed in Iran and Hezballah leader killed in Beirut last 12 hours full scale war in region highly possible now with the killing of Hamas leader in Iran. I wish IceCure was not located in Israel not adding any more shares, but not selling any either

$ICCM

[TechandBio]

UPDATE:

Company will do an offering for 30 or 40 Million. I talked to the PR point man for IceCure today. I believe it's a good thing to grow business hopefully the offering is at way higher prices. Time will tell if management can execute for shareholders. I urge you to call the company and confirm this info for yourself!

$ICCM

[TechandBio]

I believe we bounce from here. This is one Israeli Biotech that will be a winner and buck the trend of companies from this country. Will add more if we dip below .70

$ICCM

[TechandBio]

I wouldn't listen to the paid bashers on other boards claiming 15 years of data needed or a head to head with lumpectomy.

Stay the course! Know what you own.

[clobal]

Patience is a virtue....needs to get over a $1.00 first.

[TechandBio]

I have the patients to wait this out 2025 should be a golden year. I do expect an offering after FDA approval to cushion the company for US commercial launch and future success.

https://www.icecure-medical.com/

Summer Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_7548b0974a425145cf30e73983d71f6b/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

$ICCM

[show_me_money]

Added three times today under .80. I'm holding.

[TechandBio]

Need to be patient hold the line! FDA panel meeting on Approval is set for November so Late q4 2024 early Q1 2025 USA FDA approval should happen for early stage breast cancer patients and then 12 months from Japanese application which is set to in by Q1 2025 so we should get approval in late 2025 early 2026 for Japanese Approval Only hiccup for USA approval would be a CRL on manufacturing of the device but not likely USA approval should be a slam dunk in my opinion.

$ICCM

[it_happens]

I have 100 stocks in my monitor. 5 were green yesterday with ICCM being one of them.

[TechandBio]

Timing is everything. Fortunes will be made. Mic drop!

$ICCM

[TechandBio]

I'm a buyer at .72 cents recently.
You got to see the angles before they are played.

[TechandBio]

What a solid day in a sea of red.

Most undervalued stock I have come across in years.

$ICCM

[clobal]

Is revenge part of your motivation on promoting this stock or do you truly believe. You went from 10 bucks to 20 in 5 posts. Not accusing...just wondering as I am a novice.

[TechandBio]

I hope the anti israel investor shorts this with dark pool trades I want to squeeze them to the poor house.

Sales should start ramping up soon.

$ICCM

[TechandBio]

This company deserves Billion dollar plus market cap=$20.00+ I did the research for you. Talked to management and have commenced talks with other companies in the medical device space to buy them.

CURES CANCER by Freezing and Killing Tumors organically.

The clowns trying to manipulate the price are going to get hit by the IceCure train!

Next Level technology company from Israel.

Only so many shares floating the ATM is being used only when it needs to be! $4 million in quarter one is modest.


$ICCM

[it_happens]

PPS easing upwards this week. Good to see.

[TechandBio]

I disagree! Volume explosion and price appreciation.

[TechandBio]

This is just the start. I gave you guys ample time to get in at the basement discount fire sale prices. This stock will hit multiple dollars and eventually $10.00+ don't sleep on it.

$ICCM

[TechandBio]

$10.00 Stock

I think a company like Pulse Bio sciences Love to see Duggan scoop it up. I talked to Pulse management last week and explained that ICCM would be a great compliment to their umbrella of minimally invasive medical device technology. I believe a medium to large cap medical device company or pharma company buys out IceCure.


260k shares average price .72


I will lead you to Victory!

Core Holding!

$ICCM

[TechandBio]

99% Cancer Free Breast Cancer Complete Response Cure Rate! after 10 years of follow up data on patients


Just went fishing for some shares this morning! Someone is tying to scare people out of their shares I just doubled up!
https://finance.yahoo.com/news/99-74-recurrence-free-rate-123000447.html

Demand for minimally invasive breast cancer treatment was overarching theme of the conference

In one independent study led by Professor Fukuma, 389 patients treated for up to 10 years had 99.74% recurrence free rate


Another independent study led by Professor Kawamoto found 0% breast cancer local recurrence in five-year follow up

ProSense® expected to gain further traction in Japan, as distribution partner Terumo Corporation plans to submit application to the Pharmaceuticals and Medical Devices Agency ("PMDA") for regulatory clearance for breast cancer in the first quarter of 2025.

Already approved in 15 countries.

Minimal invasive procedure that cures Breast Cancer independent studies around the world. Reviewed in a highly reputable medical journal.


$ICCM

[TechandBio]

Cures 97% of early breast cancer patients after 5 year follow up independent study.

Published in highly recognized medical journal.

92% Cure rate for Late stage Breast cancer patients with large Tumors



IceCure Medical's ProSense Cryoablation System

Dr. Belinda Barclay-White on Breast Tumor Cryoablation

FREEZING CANCER IN ITS TRACKS.


The Lee Family one of Asia Richest familes owns 52% of ICCM

The company has no outstanding warrants or debt

21 Million shares Floating.


Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally.


June 2024 Biz Presentation:
https://d1io3yog0oux5.cloudfront.net/_bff00726f3fc2e5c631f07f65bc0c3de/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

$ICCM

[Paullee]

shame no one cares

[TechandBio]

Cures 97% of early breast cancer patients after 5 year follow up independent study.

Published in highly recognized medical journal.

92% Cure rate for Late stage Breast cancer patients with large Tumors


FREEZING CANCER IN ITS TRACKS.


The Lee Family one of Asia Richest familes owns 52% of ICCM


Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally.



Study published in the peer reviewed journal Breast Cancer.

Excellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablation

Strategic distribution partner of ProSense® in Japan, Terumo Corporation, expects to submit an application for regulatory clearance for breast cancer in the second half of 2024


https://ir.icecure-medical.com/news-events/press-releases/detail/126/independent-study-results-in-japan-demonstrate-zero-0-breast-cancer-local-recurrence-5-years-following-treatment-with-icecures-prosense-adding-to-continued-positive-data-published-globally
[color=red]


https://ir.icecure-medical.com/news-events/press-releases/detail/134/european-study-provides-more-evidence-supporting-icecures-prosense-is-safe-effective-cryoablation-treatment-for-metastatic-and-recurrent-breast-cancer

IceCure applications: Breast Cancer early and Late Stage, Kidney Lung, Liver Cancer, Pain, and Palliative Care, Fibroadenoma Kills bad fat cells (Obesity) application on tap!
https://www.icecure-medical.com/clinical-applications/

Recap IceCure no surgery in patient setting local anesthetic insurance companies have signed on. no radiation treatment! natural freezing that kills cancer tumors for early stage breast cancer with 97% success rate after 5 Years! This is expanding with late stage breast cancer wide array of oncology indications and large tumors. Lung, Kidney and Liver Cancer Approved in 15 countries and counting sales ramping up no debt or warrants.

Summer IceCure Biz Presentation.
https://d1io3yog0oux5.cloudfront.net/_bff00726f3fc2e5c631f07f65bc0c3de/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf

$ICCM[/color]

[it_happens]

I read TechandBio's posts but usually don't reply. I view them as FYI. I do think we are on the cusp of a breakout soon here.

[TechandBio]

Cures Cancer

Early Breast Cancer after 5 year follow up 97% complete response rate for early stage breast cancer independent studies completed in multiple countries.
Highly acclaimed peered reviewed journal.
Late stage Breast cancer Data is 92% complete response rate.


ICE3 Trial - Positive Final Results

96.3% Free from local recurrence for patients treated with ProSense® Cryoablation.

100% Safe Procedure

No significant device-related adverse events or complications have been reported.

100% Doctor & Patient Satisfaction with ProSense® Procedure.

No scarring or change to the shape and size of the breast.


Billionaire owns 52% of the shares from one of the wealthiest families

Cryoablation minimally invasive no drugs needed to put the patient out only local anesthetic and the patient is home in two hours no stitches. No surgery no radiation This is very disruptive to the Cancer Space.

Approved in 15 countries.

I have been accumulating shares daily and will continue. Potential to break $10.00 and new highs. I bought PLSE at $1.30 and rode half my shares into the high teens!
Cryoablation is treating Kidney, Bone, Lung and Liver cancer and Palliative care interesting there could be an obesity angle as well as the Freezing temps kills tumors and bad fat cells.. Non Invasive Medicine is growing and as we go move forward in medicine these area of medicine will grow leaps and bounds.



Harvard Health Blog The skinny on freezing fat
https://www.health.harvard.edu/blog/the-skinny-on-freezing-fat-2020031218990#:~:text=Average%20reduction%20in%20fat%20ranges,depending%20on%20the%20desired%20results.


IceCure Medical's ProSense Cryoablation System

$ICCM